FDA approves first drug to slow decline of Alzheimer’s disease

Ronald C. Petersen, director of the Mayo Clinic’s Alzheimer’s Disease Research Center, said in an interview before the FDA action that an approval would be a “plus for our patients,” though the effect of the medicine may be modest. He said the drug “is not penicillin for Alzhiemer’s,” referring to the 20th century discovery of a treatment for bacterial infections. Nevertheless, he said, aducanumab is a “reasonable therapeutic approach” that probably will be combined with other drugs developed in coming years.

View original article here Source

Related Posts